Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Evoke Pharma (EVOK) Equity Average (2020 - 2025)

Historic Equity Average for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $3.9 million.

  • Evoke Pharma's Equity Average rose 970.82% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 970.82%. This contributed to the annual value of $2.2 million for FY2024, which is 19622.2% up from last year.
  • Evoke Pharma's Equity Average amounted to $3.9 million in Q3 2025, which was up 970.82% from $5.1 million recorded in Q2 2025.
  • Evoke Pharma's Equity Average's 5-year high stood at $6.9 million during Q2 2021, with a 5-year trough of -$1.7 million in Q4 2023.
  • Moreover, its 5-year median value for Equity Average was $3.9 million (2025), whereas its average is $3.6 million.
  • Per our database at Business Quant, Evoke Pharma's Equity Average plummeted by 13590.64% in 2023 and then surged by 220258.59% in 2024.
  • Over the past 5 years, Evoke Pharma's Equity Average (Quarter) stood at $4.2 million in 2021, then increased by 15.48% to $4.8 million in 2022, then crashed by 135.91% to -$1.7 million in 2023, then skyrocketed by 430.85% to $5.7 million in 2024, then plummeted by 32.28% to $3.9 million in 2025.
  • Its Equity Average stands at $3.9 million for Q3 2025, versus $5.1 million for Q2 2025 and $6.4 million for Q1 2025.